Anti-tumour necrosis factor-alpha antibody oral

Drug Profile

Anti-tumour necrosis factor-alpha antibody oral

Alternative Names: Anti-TNF-alpha antibody oral; Arthrofoon; Artrofoon

Latest Information Update: 31 May 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Materia Medica Holding Research and Production Company
  • Developer Materia Medica Holdings
  • Class Antibodies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 28 Jun 2007 Data presented at the Annual European Congress of Rheumatology (EULAR-2007) added to the adverse events and Rheumatic Disease therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top